23andMe: The $6 Billion DNA Dream That Filed for Bankruptcy
Published October 29, 2026
23andMe, the company that turned spit kits into a cultural phenomenon, filed for Chapter 11 bankruptcy protection in March 2025, its market value down from nearly $6 billion at its peak to under $20 million. Co-founder Anne Wojcicki resigned as chief executive the same day so she could bid for the company herself. A one-time purchase with no repeat business, a devastating 2023 data breach, and years of losses had left the pioneer of consumer genetics with nowhere left to go.
On 23 March 2025, genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in a federal court in Missouri, announcing it would seek to sell substantially all of its assets. The same day, co-founder and chief executive Anne Wojcicki resigned, saying she stepped down to be in the best position to bid for the company as an independent buyer. It was a stunning fall for a firm once valued at nearly $6 billion: by the close of trading the next day, its market capitalization had shrunk to less than $20 million, and its shares traded for under a dollar.
23andMe had been founded in 2006 by Wojcicki, Linda Avey and Paul Cusenza with a genuinely radical promise: that ordinary people could mail in a saliva sample and learn about their ancestry and health risks without a doctor's referral. The kits became a cultural phenomenon, bought as holiday gifts and talked about at dinner tables, and the company collected genetic data from more than 15 million customers. In 2021 it went public through a merger with a special-purpose acquisition company led by Richard Branson, at an initial valuation of $3.5 billion that briefly rose toward $6 billion.
The business model, however, had a hole at its centre. A DNA test is something most customers buy once. There is little reason to spit in a tube a second time, and 23andMe never found a second act that made money. Attempts to expand into drug development and subscription health services burned cash without producing sustainable revenue, and the company never turned a profit despite raising more than $1 billion from investors. As the kit market saturated, sales faded and losses mounted; by 2024 the company was losing hundreds of millions a year, cut 40 percent of its workforce, and saw its entire independent board resign in a single day.
A data breach then compounded the damage. In October 2023, hackers using recycled passwords accessed the personal information of nearly 7 million customers over five months, including sensitive genetic and ancestry data. The breach produced a cascade of lawsuits and a $30 million class-action settlement, and it badly damaged trust in a company whose entire business rested on customers handing over their DNA. State attorneys general warned customers to consider deleting their data as the bankruptcy approached, and the question of who would own 15 million people's genetic information became a national privacy debate.
The bankruptcy filing listed estimated assets and liabilities of between $100 million and $500 million, with $35 million in financing to keep the lights on during a court-supervised sale. Wojcicki had tried repeatedly to take the company private, but a board committee rejected her bids, including one shortly before the filing. In the sale process that followed, drugmaker Regeneron initially appeared to be the buyer, but Wojcicki's nonprofit, the TTAM Research Institute, outbid it with a $305 million offer for substantially all the assets. A bankruptcy court approved that sale in late June 2025, and it closed the following month, returning the company to its founder's orbit.
Wojcicki's stake had been worth roughly $1.3 billion at the company's peak; by the bankruptcy it was a fraction of that. The wider lesson is less about one founder than about the shape of the business. A beloved product is not the same as a durable company. When revenue depends on constantly finding new buyers for something existing customers never need again, growth eventually stalls, and no amount of brand affection or scientific ambition can fill the gap. 23andMe proved that millions of people wanted to read their own DNA. It never proved that enough of them would pay for it twice.
The lesson: A product customers buy once is a marketing business, not a durable one: without repeat revenue, even a beloved brand and 15 million customers cannot outrun its own costs.
Source: original reporting · How we source stories